News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Sina Haftchenary

Articles by Sina Haftchenary

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

ByKevin Kalinsky, MD, MS,Erika P. Hamilton, MD,Laura Spring,Peter A. Fasching,Sandra Franco, MD,Richard De Boer,Javier Cortes,Dejan Juric,Aditya Bardia, MD, MPH, FASCO,Sina Haftchenary,Agnes Lteif,Juan Pablo Zarate,Liyi Cen,Patrick Neven, MD, PhD

April 27th 2023

54 Quality of Life With Ribociclib Plus Aromatase Inhibitor vs Abemaciclib Plus Aromatase Inhibitor as First-line Treatment of HR+/HER2− Advanced Breast Cancer, Assessed via Matching- Adjusted Indirect Comparison (MAIC)

ByHope S. Rugo, MD,Joyce O'Shaughnessy, MD,Komal Jhaveri,Sara M. Tolaney, MD, MPH,Fatima Cardoso,Aditya Bardia, MD, MPH, FASCO,Purnima Pathak,Sina Haftchenary,Peter A. Fasching

April 26th 2023

Latest Updated Articles

Trending on CancerNetwork

FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma

How ADCs are Replacing Chemotherapy as Breast Cancer Treatment

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

© 2025 MJH Life Sciences^®

All rights reserved.